Current Development in the Evaluation Methods of Pulmonary Drug Delivery System

Shaji, Jessy; Shaikh, Mahmood

doi:10.4172/pharmaceutical-sciences.1000118

Cited by 9 publications

(4 citation statements)

References 105 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…INH dissolution requires more extensive discussion. To date there are no pharmacopoeial dissolution method for inhalatory formulations and no single in vitro method has emerged as the ideal choice for performing dissolution tests and to estimate in vivo solubility in the lung fluids ( 56 , 57 ). The reason is that lungs have unique features that are difficult to replicate in vitro , such as extremely small amount of aqueous fluid and the presence of lung mucus and surfactant ( 56 – 59 ).…”

Section: Resultsmentioning

confidence: 99%

Iron-Based Metal-Organic Frameworks as a Theranostic Carrier for Local Tuberculosis Therapy

et al. 2018

View full text Add to dashboard Cite

PurposeThe purpose of the study was initial evaluation of applicability of metal organic framework (MOF) Fe-MIL-101-NH2 as a theranostic carrier of antituberculous drug in terms of its functionality, i.e. drug loading, drug dissolution, magnetic resonance imaging (MRI) contrast and cytotoxic safety.MethodsFe-MIL-101-NH2 was characterized using X-ray powder diffraction, FTIR spectrometry and scanning electron microscopy. The particle size analysis was determined using laser diffraction. Magnetic resonance relaxometry and MRI were carried out on phantoms of the MOF system suspended in polymer solution. Drug dissolution studies were conducted using Franz cells. For MOF cytotoxicity, commercially available fibroblasts L929 were cultured in Eagle’s Minimum Essential Medium supplemented with 10% fetal bovine serum.ResultsMOF particles were loaded with 12% of isoniazid. The particle size (3.37–6.45 μm) depended on the micronization method used. The proposed drug delivery system can also serve as the MRI contrast agent. The drug dissolution showed extended release of isoniazid. MOF particles accumulated in the L929 fibroblast cytoplasmic area, suggesting MOF release the drug inside the cells. The cytotoxicity confirmed safety of MOF system.ConclusionsThe application of MOF for extended release inhalable system proposes the novel strategy for delivery of standard antimycobacterial agents combined with monitoring of their distribution within the lung tissue.

show abstract

Section: Resultsmentioning

confidence: 99%

Iron-Based Metal-Organic Frameworks as a Theranostic Carrier for Local Tuberculosis Therapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…There, it interacts with its target receptor, exerting its therapeutic influence. The effect's amplitude depends on the drug's retention in the alveoli [150,154]. Different devices can be used for pulmonary drug delivery.…”

Section: Strategies For Pulmonary Deliverymentioning

confidence: 99%

Could the Lung Be a Gateway for Amphotericin B to Attack the Army of Fungi?

Patricio

Pereira²,

Sarcinelli

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Fungal diseases are a significant cause of morbidity and mortality worldwide, primarily affecting immunocompromised patients. Aspergillus, Pneumocystis, and Cryptococcus are opportunistic fungi and may cause severe lung disease. They can develop mechanisms to evade the host immune system and colonize or cause lung disease. Current fungal infection treatments constitute a few classes of antifungal drugs with significant fungi resistance development. Amphotericin B (AmB) has a broad-spectrum antifungal effect with a low incidence of resistance. However, AmB is a highly lipophilic antifungal with low solubility and permeability and is unstable in light, heat, and oxygen. Due to the difficulty of achieving adequate concentrations of AmB in the lung by intravenous administration and seeking to minimize adverse effects, nebulized AmB has been used. The pulmonary pathway has advantages such as its rapid onset of action, low metabolic activity at the site of action, ability to avoid first-pass hepatic metabolism, lower risk of adverse effects, and thin thickness of the alveolar epithelium. This paper presented different strategies for pulmonary AmB delivery, detailing the potential of nanoformulation and hoping to foster research in the field. Our finds indicate that despite an optimistic scenario for the pulmonary formulation of AmB based on the encouraging results discussed here, there is still no product registration on the FDA nor any clinical trial undergoing ClinicalTrial.gov.

show abstract

“…Pulmonary drug delivery (PDD) offers the possibility to treat both local and systemic diseases (1). Several advantages of administering drugs via the lungs in comparison to oral drug delivery are supported (2).…”

Section: Introductionmentioning

confidence: 99%

Development of meloxicam potassium-containing co-spray-dried inhalation powder with sodium stearate

Benke

Szabó‐Révész

Ambrus

2021

APH

View full text Add to dashboard Cite

Pulmonary drug delivery (PDD) has potential for both local and systemic therapy. Our research group is focus- ing on the development of dry powder inhalation (DPI) systems for PDD due to their beneficial properties. Although there is not yet a marketed inhalation product for non-steroidal anti-inflammatory drugs (NSAIDs), their therapeutic use in sev- eral lung diseases is well established and successful DPI developments have been performed with them. Sodium stearate (NaSt) is a promising excipient for DPI development, but its role in NSAIDs has not yet been investigated. Thus, the aim was to study DPI samples produced by co-spray-drying, applying meloxicam potassium (MXP) as an NSAID drug, and different concentrations (0-2 w/w%) of NaSt. Physicochemical investigations, in vitro lung deposition, and in vitro drug release measurements were performed. It can be stated that co-spray-drying of MXP with NaSt resulted in remarkable morphological differences by increasing the concentration of NaSt, which had a positive effect on cohesive work. Further- more, applying of NaSt accelerates the dissolution in simulated lung fluid (SLF). NaSt as excipient has a future for the formulation of the DPI systems because there are in the development focus the attaintment of the higher FPF values and improvement of dissolution in SLF.

show abstract

Current Development in the Evaluation Methods of Pulmonary Drug Delivery System

Cited by 9 publications

References 105 publications

Iron-Based Metal-Organic Frameworks as a Theranostic Carrier for Local Tuberculosis Therapy

Iron-Based Metal-Organic Frameworks as a Theranostic Carrier for Local Tuberculosis Therapy

Could the Lung Be a Gateway for Amphotericin B to Attack the Army of Fungi?

Development of meloxicam potassium-containing co-spray-dried inhalation powder with sodium stearate

Contact Info

Product

Resources

About